{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:45:27Z","timestamp":1791254727955,"version":"4.1.0"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008510","name":"University of Maryland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008510","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH","award":["UM1AI148689 and U01AI155300"],"award-info":[{"award-number":["UM1AI148689 and U01AI155300"]}]},{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"crossref","award":["INV-030857"],"award-info":[{"award-number":["INV-030857"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bill & Melinda Gates Medical Research Institute"},{"name":"BioNTech"}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"DOI":"10.1371\/journal.ppat.1012309","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T17:48:10Z","timestamp":1719510490000},"page":"e1012309","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["A new landscape for malaria vaccine development"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2450-8015","authenticated-orcid":true,"given":"Alexander J.","family":"Laurenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3874-581X","authenticated-orcid":true,"given":"Matthew B.","family":"Laurens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"ppat.1012309.ref001","volume-title":"WHO recommends groundbreaking malaria vaccine for children at risk","year":"2021"},{"key":"ppat.1012309.ref002","article-title":"Malaria Vaccine Implementation Programme (MVIP) Programme Advisory Group (PAG). Full Evidence Report on the RTS,S\/AS01 Malaria Vaccine.","year":"2021","journal-title":"SAGE Yellow Book"},{"issue":"10426","key":"ppat.1012309.ref003","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0140-6736(23)02743-5","article-title":"Malaria vaccines for children: and now there are two","volume":"403","author":"V Moorthy","year":"2024","journal-title":"Lancet"},{"key":"ppat.1012309.ref004","unstructured":"Global Malaria Programme (GMP), World Health Organization. World Malaria Report 2023. 2023."},{"key":"ppat.1012309.ref005","volume-title":"WHO recommends R21\/Matrix-M vaccine for malaria prevention in updated advice on immunization","year":"2023"},{"issue":"10426","key":"ppat.1012309.ref006","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","article-title":"Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial","volume":"403","author":"MS Datoo","year":"2024","journal-title":"Lancet"},{"key":"ppat.1012309.ref007","volume-title":"Malaria vaccines: preferred product characteristics and clinical development considerations","year":"2022"},{"issue":"11","key":"ppat.1012309.ref008","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa2026330","article-title":"Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention","volume":"385","author":"D Chandramohan","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"ppat.1012309.ref009","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1242\/jeb.00644","article-title":"Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine","volume":"206","author":"TC Luke","year":"2003","journal-title":"J Exp Biol"},{"issue":"1","key":"ppat.1012309.ref010","first-page":"964","volume":"22","author":"TL Richie","year":"2023","journal-title":"Sporozoite immunization: innovative translational science to support the fight against malaria. Expert Rev Vaccines"},{"issue":"1","key":"ppat.1012309.ref011","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41541-021-00345-0","article-title":"Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice.","volume":"6","author":"KL Mallory","year":"2021","journal-title":"NPJ Vaccines."},{"issue":"1","key":"ppat.1012309.ref012","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41541-022-00577-8","article-title":"mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum.","volume":"7","author":"CTH Hayashi","year":"2022","journal-title":"NPJ Vaccines"},{"issue":"9","key":"ppat.1012309.ref013","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/s41590-023-01562-6","article-title":"mRNA vaccine against malaria tailored for liver-resident memory T cells","volume":"24","author":"M Ganley","year":"2023","journal-title":"Nat Immunol"},{"issue":"1","key":"ppat.1012309.ref014","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41541-023-00783-y","article-title":"mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response.","volume":"9","author":"PV Scaria","year":"2024","journal-title":"NPJ Vaccines."},{"key":"ppat.1012309.ref015","unstructured":"University of Oxford. A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21 [Internet]. 2023 Jul. Report No.: NCT05357560. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05357560."},{"key":"ppat.1012309.ref016","doi-asserted-by":"crossref","first-page":"251513552211002","DOI":"10.1177\/25151355221100218","article-title":"Predicting epitopes for vaccine development using bioinformatics tools","volume":"10","author":"V Yurina","year":"2022","journal-title":"Ther Adv Vaccines Immunother"},{"issue":"8","key":"ppat.1012309.ref017","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41576-021-00349-5","article-title":"Advances and opportunities in malaria population genomics","volume":"22","author":"DE Neafsey","year":"2021","journal-title":"Nat Rev Genet"},{"issue":"3","key":"ppat.1012309.ref018","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/21645515.2019.1669415","article-title":"RTS,S\/AS01 vaccine (Mosquirix): an overview.","volume":"16","author":"MB Laurens","year":"2020","journal-title":"Hum Vaccines Immunother."},{"issue":"1","key":"ppat.1012309.ref019","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41541-023-00714-x","article-title":"Protective antibody threshold of RTS,S\/AS01 malaria vaccine correlates antigen and adjuvant dose in mouse model","volume":"8","author":"CJ Genito","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"1","key":"ppat.1012309.ref020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41541-023-00613-1","article-title":"Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design","volume":"8","author":"C Loos","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"1","key":"ppat.1012309.ref021","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1038\/s41467-023-40151-x","article-title":"Affinity-matured homotypic interactions induce spectrum of PfCSP structures that influence protection from malaria infection.","volume":"14","author":"GM Martin","year":"2023","journal-title":"Nat Commun.Jul 28"},{"key":"ppat.1012309.ref022","author":"Malaria vaccines. World Health Organization","year":"2024","journal-title":"Immunization, Vaccines and Biologicals"},{"issue":"11","key":"ppat.1012309.ref023","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S1473-3099(23)00276-1","article-title":"Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trial","volume":"23","author":"I Sagara","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"ppat.1012309.ref024","article-title":"A randomized first-in-human Phase 1 trial of differentially adjuvanted Pfs48\/45 malaria vaccines in Burkinab\u00e9 adults","author":"BA Tiono","year":"2024","journal-title":"J Clin Invest"},{"issue":"7","key":"ppat.1012309.ref025","doi-asserted-by":"crossref","first-page":"e2636","DOI":"10.1371\/journal.pone.0002636","article-title":"Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51.","volume":"3","author":"Y Wu","year":"2008","journal-title":"PLoS ONE"}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1012309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T17:49:08Z","timestamp":1719510548000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1012309"}},"subtitle":[],"editor":[{"given":"Audrey Ragan","family":"Odom John","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1012309","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,27]]}}}